Profile

On Cancer: Meet Radiation Oncologist Simon Powell

By Celia Gittelson, BA  |  Friday, January 24, 2014
Pictured: Simon Powell Dr. Powell's research interestes include the role of DNA repair deficiencies in human breast cancer; breast cancer genetics and the function of BRCA1 and BRCA2 proteins; and the optimization of radiation therapy planning and delivery for both early-stage and advanced breast cancer.

Simon Powell, Chair of the Department of Radiation Oncology, took time recently to talk about his own research as well the collaborative investigations undertaken by Memorial Sloan Kettering’s Imaging and Radiation Sciences Program (IMRAS), of which he is a member. IMRAS focuses on looking at how the effects of radiation in cells can be observed by imaging and other biological measures — and how the information gained can be used to improve patient outcomes.

One of the reasons I joined Memorial Sloan Kettering Cancer Center was because of the great opportunities here to do translational and multidisciplinary cancer research. An outstanding example of this is our Imaging and Radiation Sciences program (IMRAS).

The program focuses on looking at how the effects of radiation — in cells, in mouse models, and in people — can be observed by imaging and other biological measures. Knowing as much as possible about how a tumor responds to radiation enables us to more accurately guide treatment decisions and develop new treatment strategies. IMRAS reflects collaborative investigations across the Department of Radiation Oncology, the Department of Medical Physics, the Molecular Imaging and Therapy Service, and the Department of Radiology.

Imaging has made it possible to evaluate how effective radiation therapy is, both during and after treatment. Sophisticated technologies that already exist give us a lot of information about how a tumor is responding, but IMRAS members are working to develop even more advanced tools to image the effects of radiation on cells — tools that we hope to eventually translate into use in patients.

For example, the presence of hypoxia (a low concentration of oxygen) in tumors is common, and tumor hypoxia is known to compromise the effectiveness of radiation and chemotherapy. IMRAS members are investigating the biological underpinnings of tumor hypoxia imaging and are working on novel imaging methods to measure hypoxia status before, during, and after treatment. The more precisely we can identify and quantify tumor hypoxia, the more we’ll be able to improve patient outcomes.

How Genetics Affects Radiation Response

Another field of great interest to us is radiation genomics. Broadly speaking, radiation genomics recognizes that when you irradiate people they don’t all respond the same way. Just as there are genetic factors that control the way people respond to drugs, there are genetic factors that influence the way they respond to radiation. So both genetic and tumor-specific factors may contribute to the way a tumor responds to a fixed dose of radiation. Ultimately, we want to understand in real patients, exposed to real doses of radiation, why some respond well and others poorly.

A project in my laboratory is aimed at learning more about this variation in radiation sensitivity. We’ve taken lymphoid cell lines from individuals whose entire genomes have been sequenced and we’ve irradiated them. Then we’ve looked at the way the cells handle the radiation. What we see is a spectrum of response that exactly mirrors what we observe in people.

Then, because these genomes are fully known, we can do association analyses. These are genome-wide association studies to attempt to relate what it is about the radiation-sensitive or resistant people that makes them sensitive or resistant. We’re doing these studies in collaboration with colleagues in Memorial Hospital’s Clinical Genetics Service and the Sloan Kettering Institute’s Computational Biology Program and are looking to discover whether there are common parts of the genome that associate with radiation sensitivity or resistance.

Understanding these variations will help radiation oncologists make the best treatment decisions for each patient. For example, if we know a tumor has built-in radiation resistance mechanisms we might choose any one of a number of options — we might not use radiation at all, perhaps use a higher dose, or use a drug to make the tumor more radiosensitive.

We’re entering a new and exciting era in radiation oncology, and these are just several of the many initiatives and research efforts under way at Memorial Sloan Kettering.

This profile was featured in Memorial Sloan Kettering's 2012 Annual Report.

Comments

Dear sir, how are you? I hope this letter will find you in good spirits. My daughter Dr. V. Manasa has completed her M.B.B.S (Medicine) from Kakatiya Medical College, Warangal, India. She would like to do her Externship in your Cancer Research Center, under a professor (Medical Doctor) guidance for a period of three months with out any financial assistance from the Institute. She will meet her travel, living expenses etc., on her own. The professor with whom she would like to work should have patients. Would you kindly help in allotting her a suitable professor from medical oncology side. At the end he or she should give a certificate of training experience or work certificate for her. This is useful for her higher studies especially in writing USMLE examination. I hope you will certainly help me in this regard.
Sir, I am waiting for your kind reply.

Have a nice day.

With regards
Thanking you

Professor Rao, Thank you for your interest. To learn more about the possibility of your daughter coming to MSKCC, you can read about our International Observership Program. To learn about the program, you can go to http://www.mskcc.org/cancer-care/healthcare-professionals/international-observership or send an email to intnlprg@mskcc.org.

Add a Comment

Your e-mail address is kept private and will not be shown publicly.

More information about formatting options